Publications Featuring Simoa Accelerator Lab


Publications Featuring Simoa Accelerator Lab

1. Bogoslovsky T, Wilson D, Chen Y, et al. Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury. J Neurotrauma. 2017;34(1):66-73.

2. Mielke MM, Hagen CE, Wennberg AMV, et al. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurol. 2017;

3. Janelidze S, Stomrud E, Palmqvist S, et al. Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016;6:26801.

4. Song L, Lachno DR, Hanlon D, et al. A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics. Alzheimers Res Ther. 2016;8(1):58.

5. Sokoll LJ, Zhang Z, Chan DW, et al. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?. J Urol. 2016;195(2):330-6.

6. Lepor H, Cheli CD, Thiel RP, et al. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM), as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study. BJU Int. 2012;109(12):1770-5.

7. Song L, Hanlon DW, Chang L, et al. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease. J Immunol Methods. 2011;372(1-2):177-86.

8. Wilson DH, Hanlon DW, Provuncher GK, et al. Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem. 2011;57(12):1712-21.

9. Mattsson, N., Zetterberg, H., Janelidze, S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C., Jeromin, A., Hanlon, D., Song, L., Shaw, L.M. Trojanowski, J.Q., Weiner, M.W., Hansson, O. and Blennow, K. 2016.  Plasma Tau in Alzheimer’s Disease. Neurology. 87:1827-35.

10. Mondellow, S., Burki, A., Barzo, P., Randall, J., Provuncher, G., Hanlon, D., Wilson, D., Kobeissy, F., Jeromin, A.  2014.  CSF and plasma amyloid-b temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury.  Sci. Rep. 4:6446.

11. Alosco ML, Tripodis Y, Jarnagin J, Baugh CM, Martin B, Chaisson CE, Estochen N, Song L, Cantu RC, Jeromin A, Stern RA. 2016.  Repetitive head impact exposure and later-life plasma total tau in former National Football League players. Alzheimers Dement (Amst). 2016 Dec 10;7:33-40. doi: 10.1016/j.dadm.2016.11.003.

12. Gill J, Latour L, Diaz-Arrastia R, Motamedi V, Turtzo C, Shahim P, Mondello S, DeVoto C, Veras E, Hanlon D, Song L, Jeromin A. 2018. Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities acutely following a mild traumatic brain injury. Neurology. Sep 12. doi: 10.1212/WNL.0000000000006321.

13. Matthew P. Pase, PhD; Alexa S. Beiser, PhD; Jayandra J. Himali, PhD; Claudia L. Satizabal, PhD; Hugo J. Aparicio, MD; Charles DeCarli, MD; Geneviève Chêne, MD, PhD; Carole Dufouil, PhD; Sudha Seshadri, MD. 2019. Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. JAMA Neurollgy. Mar 4. doi: 10.1001/jamaneurol.2018.4666